NCI-H1155Homo sapiens (Human)Cancer cell line

Also known as: NCI-1155, NCIH1155, H-1155, H1155

🤖 AI SummaryBased on 12 publications

Quick Overview

Human lung cancer cell line with potential for drug sensitivity studies

Detailed Summary

The NCI-H1155 cell line is a human-derived lung cancer cell line that has been extensively studied in cancer research. It is known for its utility in investigating small cell lung cancer (SCLC) and has been used in various studies to understand molecular pathways and therapeutic targets. This cell line is particularly valuable for its role in identifying dysregulated pathways and potential therapeutic strategies, such as the role of PARP1 and EZH2 in SCLC. Additionally, it has been utilized in studies involving proteomic profiling and drug sensitivity assays, contributing to the development of targeted therapies. The cell line's characteristics make it a key resource for researchers exploring the complexities of lung cancer biology and treatment options.

Research Applications

Small cell lung cancer (SCLC) researchProteomic profilingDrug sensitivity studiesTherapeutic target identification

Key Characteristics

Used in studies of PARP1 and EZH2 in SCLCUtilized for proteomic and transcriptomic analysisRelevant for understanding dysregulated pathways in cancer
Generated on 6/17/2025

Basic Information

Database IDCVCL_1456
SpeciesHomo sapiens (Human)
Tissue SourceLymph node[UBERON:UBERON_0000029]

Donor Information

Age36
Age CategoryAdult
SexMale
Racecaucasian

Disease Information

DiseaseLung large cell carcinoma
LineageLung
SubtypeLarge Cell Lung Carcinoma
OncoTree CodeLCLC

DepMap Information

Source TypeATCC
Source IDACH-000980_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Arg273His (c.818G>A)Homozygous-Unknown, PubMed=16264262
MutationSimplePTENp.Arg233Ter (c.697C>T)Heterozygous-PubMed=28683746, PubMed=24042735
MutationSimpleKRASp.Gln61His (c.183A>T)Unspecified-DOI=10.6342/NTU.2004.01000
MutationSimpleAPCp.Arg232Ter (c.694C>T)Heterozygous-Unknown, Unknown

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
12
D13S317
14
D16S539
9
D18S51
16
D19S433
16.2
D21S11
32.2
D2S1338
17
D3S1358
15
D5S818
10
D7S820
8
D8S1179
14,16
FGA
26
Penta D
9
Penta E
10
TH01
6
TPOX
8
vWA
15
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

From clinical specimens to human cancer preclinical models -- a journey the NCI-cell line database-25 years later.

Aldige C.R., Wistuba I.I., Minna J.D.

J. Cell. Biochem. 121:3986-3999(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

LMO1 functions as an oncogene by regulating TTK expression and correlates with neuroendocrine differentiation of lung cancer.

Minna J.D., Wistuba I.I., Pertsemlidis A.

Oncotarget 9:29601-29618(2018).

Chemistry-first approach for nomination of personalized treatment in lung cancer.

Posner B.A., Minna J.D., Kim H.S., White M.A.

Cell 173:864-878.e29(2018).

Differential effector engagement by oncogenic KRAS.";

McCormick F.

Cell Rep. 22:1889-1902(2018).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

Reconstructing targetable pathways in lung cancer by integrating diverse omics data.

Cao X.-H., Nesvizhskii A.I., Chinnaiyan A.M.

Nat. Commun. 4:2617.1-2617.13(2013).

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

Heymach J.V.

Cancer Discov. 2:798-811(2012).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma.

Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.

Cancer Sci. 101:1891-1896(2010).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

A gene-alteration profile of human lung cancer cell lines.";

Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.

Hum. Mutat. 30:1199-1206(2009).

High resolution analysis of non-small cell lung cancer cell lines by whole genome tiling path array CGH.

Gazdar A.F., Lam S., MacAulay C., Lam W.L.

Int. J. Cancer 118:1556-1564(2006).

Mutations of the BRAF gene in human cancer.";

Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.

Nature 417:949-954(2002).

Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.

Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.

Oncogene 19:4632-4639(2000).

Mutation and expression of the DCC gene in human lung cancer.";

Yokota J.

Neoplasia 2:300-305(2000).

Comprehensive analysis of p53 gene mutation characteristics in lung carcinoma with special reference to histological subtypes.

Fujita T., Kiyama M., Tomizawa Y., Kohno T., Yokota J.

Int. J. Oncol. 15:927-934(1999).

NCI-Navy Medical Oncology Branch cell line data base.";

Carney D.N., Minna J.D., Mulshine J.L.

J. Cell. Biochem. Suppl. 24:32-91(1996).

Mutations and altered expression of p16INK4 in human cancer.";

Harris C.C.

Proc. Natl. Acad. Sci. U.S.A. 91:11045-11049(1994).

Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation.

Linnoila R.I.

Oncogene 7:743-749(1992).

Neuromedin B is present in lung cancer cell lines.";

Giaccone G., Battey J., Gazdar A.F., Oie H.K., Draoui M., Moody T.W.

Cancer Res. 52:2732s-2736s(1992).

p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.

Gazdar A.F.

Oncogene 7:171-180(1992).

Web Resources